Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.72%
0%
3.72%
6 Months
-2.5%
0%
-2.5%
1 Year
-25.0%
0%
-25.0%
2 Years
-12.95%
0%
-12.95%
3 Years
-58.05%
0%
-58.05%
4 Years
-53.77%
0%
-53.77%
5 Years
-17.86%
0%
-17.86%
Scancell Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
41.69%
EBIT Growth (5y)
-173.35%
EBIT to Interest (avg)
-8.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.43
Tax Ratio
35.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-26.36
EV to EBIT
-6.69
EV to EBITDA
-7.11
EV to Capital Employed
-21.88
EV to Sales
21.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Apr'23
Apr'23
Apr'22
Change(%)
Net Sales
5.30
0.00
Operating Profit (PBDIT) excl Other Income
-11.00
-13.50
18.52%
Interest
1.20
1.80
-33.33%
Exceptional Items
0.00
-6.30
100.00%
Consolidate Net Profit
-11.90
-4.60
-158.70%
Operating Profit Margin (Excl OI)
-2,261.40%
0.00%
-226.14%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2023 is 0.00% vs 0.00% in Apr 2022
Consolidated Net Profit
YoY Growth in year ended Apr 2023 is -158.70% vs 70.32% in Apr 2022
About Scancell Holdings Plc 
Scancell Holdings Plc
Pharmaceuticals & Biotechnology
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Company Coordinates 
Company Details
Department of Clinical Oncology, Hucknall Road OXFORD None : OX4 4GP
Registrar Details






